Cong Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cong Xia has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ben Liu
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
17 shared publications - Fangdi Zou
Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Tianjin, China
17 shared publications - Haixin Li
Tianjin Tissue Bank, Key Laboratory of Cancer Prevention and Therapy, Tianjin Key Laboratory of Digestive Cancer, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Prevention and Control of Major Diseases in the Population, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin Medical University, Tianjin, China
17 shared publications - Jie Yang
State Key Laboratory of Experimental Hematology, Key Laboratory of Cellular and Molecular Immunology in Tianjin, and Key Laboratory of Immune Microenvironment and Disease (Ministry of Education), The Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Breast Cancer Prevention and Therapy (Ministry of Education), School of Basic Medical Science, Tianjin Medical University, Tianjin 300070, China
17 shared publications - Kexin Chen
Department of Epidemiology and Biostatistics, Key Laboratory of Molecular Cancer Epidemiology, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China
17 shared publications - Lian Li
Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin’s Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin, Tianjin, China, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P.R. China
17 shared publications
Latest Publications
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in HCC mouse model.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in HCC mouse model.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Identification of CRTC2–YTHDF2 co-condensate m6A-RNAs.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Identification of CRTC2–YTHDF2 co-condensate m6A-RNAs.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
The location and function of TurboID-tagged CRTC2 are similar to wild-type CRTC2.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
The location and function of TurboID-tagged CRTC2 are similar to wild-type CRTC2.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes HCC progression dependent on YTHDF2.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes HCC progression dependent on YTHDF2.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 condensates promote HCC initiation and progression in vivo and in vitro.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 condensates promote HCC initiation and progression in vivo and in vitro.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Knockout of CRTC2 impairs proliferation of HCC cells.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Knockout of CRTC2 impairs proliferation of HCC cells.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in DEN/CCl4-HCC model.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S12 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Schematic of AAV8.sgCRTC2 gene therapy in DEN/CCl4-HCC model.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S13 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes Lenvatinib resistance in HCC.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 promotes Lenvatinib resistance in HCC.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Relationship between baseline and clinical characteristics of the patient and CRTC2 expression
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
Relationship between baseline and clinical characteristics of the patient and CRTC2 expression
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 serves as a scaffold protein to recruit YTHDF2 into condensates.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from CRTC2 Forms Co-Condensates with YTHDF2 That Enhance Translational Efficiency of m6A-Modified mRNAs to Drive Hepatocarcinogenesis and Lenvatinib Resistance
CRTC2 serves as a scaffold protein to recruit YTHDF2 into condensates.